

# TRANSIT REGISTRY - India

Authors:  
Upendra Kaul

## REGISTRY DESIGN:

Post-marketing surveillance Registry designed to determine Efficacy and Safety of **TRANSlumIna** Stent Coating System with Rapamycin Coating on a polymer free, microporous surface of the Stent.

## SOURCE:

Presentation TCT congress 2006

## PARTICIPATING CENTERS:

Fortis Hospital (New Delhi)	Dr. Upendra Kaul
SGPGIMS (Lucknow)	Dr. Nakul Sinha
Sterling Hospital (Ahmedabad)	Dr. Tejas Patel
Batra Hospital (New Delhi)	Dr. Rajiv Aggrawal
Saroj Hospital (New Delhi)	Dr. Anil Bansal

A total number of enrolled patients in this registry are **835**. Follow-up status was performed at 0-3 months (146 patients), 3-6 months (173 patients), 6-12 months (243 patients) and >12 months (273 patients).

## Baseline patient characteristics:

N = 835	
Age, y	63,4
Male, %	83,11
Diabetes mellitus, %	31,25
Hypertension, %	42,87
Acute MI, %	18,15
Unstable angina, %	62
History of MI, %	15,45
Smokers, %	22,87
Prior PCI, %	2,39

## Lesion characteristics:

Lesion location	
RCA, %	28
LAD, %	49
LCX, %	17
Ramus, %	1
Grafts, %	1
Obtuse marginal, %	4
Complex lesions – B2, C, %	78
Stented length, mm	19,46 (60% ≥ 20 mm)
Average stent diameter, mm	2,94 (80% ≤ 3 mm)


## REGISTRY ENDPOINTS:

The primary endpoint of the registry is to observe the rate of target lesion re-intervention for various patient cohorts treated with the Translumina Stent Coating Technology.


Secondary endpoint is to evaluate 12-month outcomes in patients undergoing re-intervention, including type of intervention, time since first implant, subsequent re-interventions, incidence of Q-wave MI and death.

**RESULTS:**


**Reported cardiac events at 12 months**



**Reported stent thrombosis rates**



**TRANSIT VS. WISDOM Registry, India  
Reported cardiac events at 12 months**



**CONCLUSION:**

On-site stent coating with Rapamycin on a microporous surface Translumina YUKON stent without a polymer is feasible and safe for treating the “Real world” lesions. The SAT and LAST rates are very low for a DES. The repeat intervention rates are low and comparable to other contemporary DES Registries like the WISDOM registry of the Taxus stent. Long-Term Follow-up of this registry data will be presented later in 2009.